Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Plasma cholesterol-induced lesion networks activated before regression of early, mature, and advanced atherosclerosis.

Björkegren JL, Hägg S, Talukdar HA, Foroughi Asl H, Jain RK, Cedergren C, Shang MM, Rossignoli A, Takolander R, Melander O, Hamsten A, Michoel T, Skogsberg J.

PLoS Genet. 2014 Feb 27;10(2):e1004201. doi: 10.1371/journal.pgen.1004201. eCollection 2014 Feb.

2.

Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes.

Skogsberg J, Lundström J, Kovacs A, Nilsson R, Noori P, Maleki S, Köhler M, Hamsten A, Tegnér J, Björkegren J.

PLoS Genet. 2008 Mar 14;4(3):e1000036. doi: 10.1371/journal.pgen.1000036.

3.

Altered metabolism of LDL in the arterial wall precedes atherosclerosis regression.

Bartels ED, Christoffersen C, Lindholm MW, Nielsen LB.

Circ Res. 2015 Nov 6;117(11):933-42. doi: 10.1161/CIRCRESAHA.115.307182. Epub 2015 Sep 10.

PMID:
26358193
4.

ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity.

Rong JX, Blachford C, Feig JE, Bander I, Mayne J, Kusunoki J, Miller C, Davis M, Wilson M, Dehn S, Thorp E, Tabas I, Taubman MB, Rudel LL, Fisher EA.

Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):4-12. doi: 10.1161/ATVBAHA.112.252056. Epub 2012 Nov 8.

5.

Serum Amyloid A Facilitates Early Lesion Development in Ldlr-/- Mice.

Krishack PA, Bhanvadia CV, Lukens J, Sontag TJ, De Beer MC, Getz GS, Reardon CA.

J Am Heart Assoc. 2015 Jul 17;4(7). pii: e001858. doi: 10.1161/JAHA.115.001858.

6.

Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E.

Tangirala RK, Praticó D, FitzGerald GA, Chun S, Tsukamoto K, Maugeais C, Usher DC, Puré E, Rader DJ.

J Biol Chem. 2001 Jan 5;276(1):261-6.

7.

siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids.

Tadin-Strapps M, Peterson LB, Cumiskey AM, Rosa RL, Mendoza VH, Castro-Perez J, Puig O, Zhang L, Strapps WR, Yendluri S, Andrews L, Pickering V, Rice J, Luo L, Chen Z, Tep S, Ason B, Somers EP, Sachs AB, Bartz SR, Tian J, Chin J, Hubbard BK, Wong KK, Mitnaul LJ.

J Lipid Res. 2011 Jun;52(6):1084-97. doi: 10.1194/jlr.M012872. Epub 2011 Mar 11.

8.

microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator.

Jiang H, Zhang J, Du Y, Jia X, Yang F, Si S, Wang L, Hong B.

Atherosclerosis. 2015 Dec;243(2):523-32. doi: 10.1016/j.atherosclerosis.2015.10.026. Epub 2015 Oct 23.

PMID:
26523989
9.

Inducible ApoE gene repair in hypomorphic ApoE mice deficient in the low-density lipoprotein receptor promotes atheroma stabilization with a human-like lipoprotein profile.

Eberlé D, Luk FS, Kim RY, Olivas VR, Kumar N, Posada JM, Li K, Gaudreault N, Rapp JH, Raffai RL.

Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):1759-67. doi: 10.1161/ATVBAHA.112.300605. Epub 2013 Jun 20.

10.

Hyperlipidemia and atherosclerotic lesion development in Ldlr-deficient mice on a long-term high-fat diet.

Ma Y, Wang W, Zhang J, Lu Y, Wu W, Yan H, Wang Y.

PLoS One. 2012;7(4):e35835. doi: 10.1371/journal.pone.0035835. Epub 2012 Apr 25.

11.
12.
13.

Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.

Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, Perović-Ottstadt S, Schlüter T, Kinzel O, Krol HD, Deuschle U, Burnet M, Levi M, Schmitz G, Miyazaki M, Kremoser C.

J Pharmacol Exp Ther. 2012 Dec;343(3):556-67. doi: 10.1124/jpet.112.196519. Epub 2012 Aug 23.

PMID:
22918042
14.

Stage-specific remodeling of atherosclerotic lesions upon cholesterol lowering in LDL receptor knockout mice.

Zhao Y, Ye D, Wang J, Calpe-Berdiel L, Azzis SB, Van Berkel TJ, Van Eck M.

Am J Pathol. 2011 Sep;179(3):1522-32. doi: 10.1016/j.ajpath.2011.05.020. Epub 2011 Jul 8.

15.

Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice.

Beutner F, Brendel D, Teupser D, Sass K, Baber R, Mueller M, Ceglarek U, Thiery J.

Atherosclerosis. 2012 Jun;222(2):337-43. doi: 10.1016/j.atherosclerosis.2012.03.003. Epub 2012 Mar 10.

PMID:
22446027
16.

Incremental replacement of saturated fats by n-3 fatty acids in high-fat, high-cholesterol diets reduces elevated plasma lipid levels and arterial lipoprotein lipase, macrophages and atherosclerosis in LDLR-/- mice.

Chang CL, Torrejon C, Jung UJ, Graf K, Deckelbaum RJ.

Atherosclerosis. 2014 Jun;234(2):401-9. doi: 10.1016/j.atherosclerosis.2014.03.022. Epub 2014 Apr 3.

18.

Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.

Verreth W, De Keyzer D, Davey PC, Geeraert B, Mertens A, Herregods MC, Smith G, Desjardins F, Balligand JL, Holvoet P.

Br J Pharmacol. 2007 Jun;151(3):347-55. Epub 2007 Mar 26.

19.

Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.

Guo H, Shi Y, Liu L, Sun A, Xu F, Chi J.

Arch Med Res. 2009 Jul;40(5):345-51. doi: 10.1016/j.arcmed.2009.07.006.

PMID:
19766896
20.

Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.

Yang LX, Heng XH, Guo RW, Si YK, Qi F, Zhou XB.

J Cardiovasc Pharmacol. 2013 Aug;62(2):205-11. doi: 10.1097/FJC.0b013e3182967fc0.

PMID:
23615158

Supplemental Content

Support Center